Armistice Capital, Llc Cyclo Therapeutics, Inc. (CYTH) insider trading activity

Armistice Capital, LLC is > 10% Shareholder of Cyclo Therapeutics, Inc.. Currently has a direct ownership of 15.8 Million shares of CYTH, which is worth approximately $9 Million. The most recent transaction as insider was on Sep 30, 2020, when has been sold 5,500 shares (Common Stock) at a price of $0.13 per share, resulting in proceeds of $715. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.8M

0% 3M change

0% 12M change

Total Value Held $9 Million

ARMISTICE CAPITAL, LLC Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 30 2020	SELL Open market or private sale	$715 $0.13 p/Share	5,500 Reduced 0.03%	15,795,769 Common Stock
Sep 29 2020	SELL Open market or private sale	$700 $0.14 p/Share	5,000 Reduced 0.03%	15,801,269 Common Stock
Sep 28 2020	SELL Open market or private sale	$646 $0.13 p/Share	4,966 Reduced 0.03%	15,806,269 Common Stock
Sep 24 2020	SELL Open market or private sale	$4,973 $0.13 p/Share	38,257 Reduced 0.24%	15,811,235 Common Stock
Sep 23 2020	SELL Open market or private sale	$7,000 $0.14 p/Share	50,000 Reduced 0.31%	15,849,492 Common Stock
Sep 22 2020	SELL Open market or private sale	$2,550 $0.15 p/Share	17,000 Reduced 0.11%	15,899,492 Common Stock
Sep 21 2020	SELL Open market or private sale	$15,000 $0.15 p/Share	100,000 Reduced 0.62%	15,916,492 Common Stock
Sep 16 2020	SELL Open market or private sale	$20,000 $0.16 p/Share	125,000 Reduced 0.77%	16,016,492 Common Stock
Sep 15 2020	SELL Open market or private sale	$13,133 $0.16 p/Share	82,084 Reduced 0.51%	16,141,492 Common Stock
Sep 14 2020	SELL Open market or private sale	$22,100 $0.17 p/Share	130,000 Reduced 0.79%	16,223,576 Common Stock
Sep 11 2020	SELL Open market or private sale	$28,900 $0.17 p/Share	170,000 Reduced 1.03%	16,353,576 Common Stock
Sep 10 2020	SELL Open market or private sale	$48,025 $0.17 p/Share	282,500 Reduced 1.68%	16,523,576 Common Stock
Sep 09 2020	SELL Open market or private sale	$99,103 $0.18 p/Share	550,570 Reduced 3.17%	16,806,076 Common Stock
Sep 08 2020	SELL Open market or private sale	$213,997 $0.16 p/Share	1,337,482 Reduced 7.15%	17,356,826 Common Stock
Sep 04 2020	SELL Open market or private sale	$18,240 $0.16 p/Share	114,000 Reduced 0.61%	18,694,308 Common Stock
Sep 03 2020	SELL Open market or private sale	$8,557 $0.16 p/Share	53,479 Reduced 0.28%	18,808,308 Common Stock
Aug 31 2020	BUY Open market or private sale	$3,850 $0.11 p/Share	35,000 Added 0.19%	18,861,787 Common Stock, par valu...
Aug 28 2020	BUY Open market or private sale	$8,250 $0.11 p/Share	75,000 Added 0.4%	18,896,787 Common Stock, par valu...
Aug 27 2020	BUY Open market or private sale	$6,632 $0.12 p/Share	55,263 Added 0.29%	18,971,787 Common Stock, par valu...

Also insider at

AVTX

Avalo Therapeutics, Inc. Healthcare

> 10% Shareholder

BBI

Brickell Biotech, Inc. Healthcare

> 10% Shareholder

ALIM

ALIMERA SCIENCES INC Healthcare

> 10% Shareholder

KPRX

KIORA PHARMACEUTICALS INC Healthcare

> 10% Shareholder

SAVA

CASSAVA SCIENCES INC Healthcare

> 10% Shareholder

DFRG

Del Frisco's Restaurant Group, Inc.

> 10% Shareholder

VLRX

Valeritas Holdings Inc.

> 10% Shareholder

BPTH

BIO-PATH HOLDINGS INC Healthcare

> 10% Shareholder

AYTU

AYTU BIOPHARMA, INC Healthcare

Director

ACHV

ACHIEVE LIFE SCIENCES, INC. Healthcare

> 10% Shareholder

AMAG

AMAG PHARMACEUTICALS, INC.

> 10% Shareholder

RSLS

ReShape Weightloss Inc.

> 10% Shareholder

INNV

INNOVUS PHARMACEUTICALS, INC.

> 10% Shareholder

ONTX

Onconova Therapeutics, Inc. Healthcare

> 10% Shareholder

VXRT

Vaxart, Inc. Healthcare

Director

TTPH

TETRAPHASE PHARMACEUTICALS INC

Director

TENX

TENAX THERAPEUTICS, INC. Healthcare

Director

RSLS

ReShape Lifesciences Inc. Healthcare

> 10% Shareholder

ACL